J J Feld

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome
    Jordan J Feld
    Department of Medicine and Pathology, University Health Network, University of Toronto, Canada
    Hepatology 42:53-62. 2005
  2. ncbi Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 46:1548-63. 2007
  3. ncbi Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
    Conor O'Brien
    Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Canada
    Hepatology 48:550-6. 2008
  4. ncbi Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B
    Jordan J Feld
    Department of Medicine, University of Toronto, Toronto, Canada
    Hepatology 46:1057-70. 2007
  5. ncbi Abnormal intestinal permeability in primary biliary cirrhosis
    Jordan J Feld
    Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
    Dig Dis Sci 51:1607-13. 2006
  6. ncbi The lighter side of myeloma: an easily overlooked diagnosis
    J J Feld
    Department of Gastroenterology, University of Toronto, Canada
    Gut 54:1376, 1401. 2005
  7. ncbi The liver in HIV in Africa
    Jordan J Feld
    Infectious Disease Clinic, Department of Medicine, Mulago Hospital, Kampala, Uganda
    Antivir Ther 10:953-65. 2005
  8. ncbi Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
    Y Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1800, USA
    Aliment Pharmacol Ther 31:1018-27. 2010
  9. ncbi Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review
    Jane A Little
    Vascular Medicine Branch, National Heart Lung and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Haematologica 91:1076-83. 2006
  10. ncbi Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients
    Wendy A Henderson
    Biobehavioral Unit, Symptoms Management Branch, Intramural Research Program, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD 20892, USA
    Pediatr Infect Dis J 28:724-7. 2009

Collaborators

Detail Information

Publications21

  1. ncbi Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome
    Jordan J Feld
    Department of Medicine and Pathology, University Health Network, University of Toronto, Canada
    Hepatology 42:53-62. 2005
    ..In conclusion, patients with AIH who are asymptomatic at presentation have a good prognosis and may not require immunosuppressive therapy. Cirrhosis on initial liver biopsy portends a poor prognosis in all patients with AIH...
  2. ncbi Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 46:1548-63. 2007
    ..Collectively, these mechanisms may provide a molecular basis for the improved efficacy of combination therapy...
  3. ncbi Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
    Conor O'Brien
    Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Canada
    Hepatology 48:550-6. 2008
    ....
  4. ncbi Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B
    Jordan J Feld
    Department of Medicine, University of Toronto, Toronto, Canada
    Hepatology 46:1057-70. 2007
    ....
  5. ncbi Abnormal intestinal permeability in primary biliary cirrhosis
    Jordan J Feld
    Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
    Dig Dis Sci 51:1607-13. 2006
    ..016+/-0.011) (P=NS). We conclude that the permeability of both the stomach and the small bowel is increased in patients with PBC, however, it is unclear if it is a cause, consequence, or manifestation of the disease...
  6. ncbi The lighter side of myeloma: an easily overlooked diagnosis
    J J Feld
    Department of Gastroenterology, University of Toronto, Canada
    Gut 54:1376, 1401. 2005
  7. ncbi The liver in HIV in Africa
    Jordan J Feld
    Infectious Disease Clinic, Department of Medicine, Mulago Hospital, Kampala, Uganda
    Antivir Ther 10:953-65. 2005
    ..In this review we present the available data on liver disease in HIV-infected populations in Africa and discuss relevant data from the rest of the world. In addition, we highlight important areas for further study...
  8. ncbi Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
    Y Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1800, USA
    Aliment Pharmacol Ther 31:1018-27. 2010
    ..Chronic infection with hepatitis C, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of peginterferon would be as effective, but less toxic than standard doses...
  9. ncbi Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review
    Jane A Little
    Vascular Medicine Branch, National Heart Lung and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Haematologica 91:1076-83. 2006
    ..Furthermore EPO appears to be safe in SCD, particularly when used in conjunction with HU. We outline our current therapeutic strategy for EPO use in SCD...
  10. ncbi Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients
    Wendy A Henderson
    Biobehavioral Unit, Symptoms Management Branch, Intramural Research Program, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD 20892, USA
    Pediatr Infect Dis J 28:724-7. 2009
    ..This study describes the symptomatic and pathophysiologic presentation of HCV infection in a cohort of pediatric outpatients...
  11. ncbi Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression
    Tara N Palmore
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1888, Bethesda, Maryland 20892 1888, USA
    Clin Gastroenterol Hepatol 7:1130-7. 2009
    ..We report 6 patients who experienced loss of serologic markers of hepatitis B immunity and reappearance of HBsAg in the serum as a result of a variety of acquired immune deficiencies...
  12. ncbi Epidemiology of autoimmune liver disease
    J J Feld
    Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
    J Gastroenterol Hepatol 18:1118-28. 2003
    ..In this review, the current data on the epidemiology of PBC, AIH and PSC are summarized and suggestions are made for future work in this important area...
  13. ncbi Endpoints of therapy in chronic hepatitis B
    Jordan J Feld
    From the Toronto Western Hospital Liver Centre, Department of Medicine, Division of Gastroenterology, University of Toronto, Toronto, Canada
    Hepatology 49:S96-S102. 2009
    ..Future research should be directed at development and validation of surrogate markers that accurately predict or reflect clinically relevant outcomes of chronic hepatitis B...
  14. ncbi Viral hepatitis and HIV in Africa
    Apurva A Modi
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1800, USA
    AIDS Rev 9:25-39. 2007
    ..In this review, we present the available data on coinfection in Africa with a major emphasis on prevalence, routes of transmission, prevention and treatment strategies...
  15. ncbi Hepatitis C -- identifying patients with progressive liver injury
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 43:S194-206. 2006
    ..A greater understanding of the determinants of disease progression will hopefully lead to improved utilization of existing treatments and ultimately may aid in identification of new therapeutic targets...
  16. ncbi Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland, USA
    Semin Liver Dis 26:116-29. 2006
    ..The major challenge for the clinician using these agents is the emergence of antiviral drug resistance. Long-term immune control of viral replication is key to improving patient outcome...
  17. ncbi Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 134:1917-26. 2008
    ..Liver involvement in CGD includes vascular abnormalities, which may lead to noncirrhotic portal hypertension...
  18. ncbi Hepatic abnormalities in patients with chronic granulomatous disease
    Nadeem Hussain
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892 1800, USA
    Hepatology 45:675-83. 2007
    ..Vascular lesions such as venopathy and--to a lesser extent--NRH are common. The cause and clinical consequences of venopathy await prospective evaluation...
  19. ncbi Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex
    Jordan J Feld
    Ann Intern Med 147:806-8. 2007
  20. ncbi Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C
    Ying Huang
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Gastroenterology 132:733-44. 2007
    ..To understand IFN-alpha resistance in vivo, we examined the dynamic responses to both type I and type II IFNs, human IFN (hIFN)-alpha, -gamma, and consensus IFN, in the chimpanzee model...
  21. ncbi Mechanism of action of interferon and ribavirin in treatment of hepatitis C
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Building 31, Room 9A27, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 436:967-72. 2005
    ..To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential...